Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:tertiary carboxamide
go back to main search page
Accession:CHEBI:140326 term browser browse the term
Definition:A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
Synonyms:related_synonym: Formula=CNOR3;   SMILES=N(C(*)=O)(*)*;   tertiary carboxamides



show annotations for term's descendants           Sort by:
 
acalabrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crp C-reactive protein affects expression ISO acalabrutinib affects the expression of CRP protein CTD PMID:32503877 NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
multiple interactions
affects metabolic processing
ISO CYP3A4 protein results in increased metabolism of acalabrutinib
Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of acalabrutinib]
CTD PMID:34153224 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Il6 interleukin 6 decreases expression ISO acalabrutinib results in decreased expression of IL6 protein CTD PMID:32503877 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
butachlor term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor increases activity ISO butachlor results in increased activity of AR protein CTD PMID:20143881 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases metabolic processing ISO CYP2B6 protein results in increased metabolism of butachlor CTD PMID:11133395 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing ISO CYP3A4 protein results in increased metabolism of butachlor CTD PMID:11133395 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Dio1 iodothyronine deiodinase 1 decreases activity ISO butachlor results in decreased activity of DIO1 protein CTD PMID:29228274 NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 increases activity ISO butachlor results in increased activity of NR1H4 protein CTD PMID:20143881 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases activity ISO butachlor results in increased activity of NR3C1 protein CTD PMID:20143881 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
JBrowse link
G Thrb thyroid hormone receptor beta affects binding ISO butachlor binds to THRB protein CTD PMID:28973306 NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
JBrowse link
camostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cckar cholecystokinin A receptor increases expression EXP camostat results in increased expression of CCKAR mRNA CTD PMID:10458643 NCBI chr14:57,292,397...57,300,747
Ensembl chr14:57,292,397...57,300,747
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA] CTD PMID:27773435 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA] CTD PMID:25766432 PMID:27773435 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCND1 protein] CTD PMID:25104499 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
increases expression
ISO mirdametinib inhibits the reaction [camostat results in increased expression of CCND3 protein] CTD PMID:25104499 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
JBrowse link
G Ccne1 cyclin E1 increases expression
multiple interactions
ISO camostat results in increased expression of CCNE1 protein
mirdametinib inhibits the reaction [camostat results in increased expression of CCNE1 protein]
CTD PMID:25104499 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of COL1A1 mRNA] CTD PMID:25766432 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of COL3A1 mRNA] CTD PMID:25766432 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of CYBB mRNA] CTD PMID:25766432 NCBI chr  X:13,360,583...13,392,517
Ensembl chr  X:13,359,430...13,392,586
JBrowse link
G Egr1 early growth response 1 multiple interactions
increases expression
ISO mirdametinib inhibits the reaction [camostat results in increased expression of EGR1 mRNA] CTD PMID:25104499 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO camostat results in increased expression of and results in increased secretion of FGF21 protein CTD PMID:30920846 NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO mirdametinib inhibits the reaction [camostat results in increased expression of FOS mRNA] CTD PMID:25104499 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Ier3 immediate early response 3 increases expression ISO camostat results in increased expression of IER3 mRNA CTD PMID:25104499 NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
increases phosphorylation
ISO camostat results in increased expression of JUN mRNA
camostat results in increased phosphorylation of JUN protein
CTD PMID:25104499 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression ISO camostat results in increased expression of JUNB mRNA CTD PMID:25104499 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein] CTD PMID:25104499 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions
ISO camostat results in increased phosphorylation of MAPK3 protein
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]
CTD PMID:25104499 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mki67 marker of proliferation Ki-67 increases expression
multiple interactions
ISO camostat results in increased expression of MKI67 protein
mirdametinib inhibits the reaction [camostat results in increased expression of MKI67 protein]
CTD PMID:25104499 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Nos3 nitric oxide synthase 3 increases expression EXP camostat results in increased expression of NOS3 mRNA CTD PMID:10458643 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of NOX1 mRNA] CTD PMID:25766432 NCBI chr  X:97,279,058...97,332,291
Ensembl chr  X:97,279,056...97,302,236
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
increases expression
ISO mirdametinib inhibits the reaction [camostat results in increased expression of PCNA protein] CTD PMID:25104499 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Plg plasminogen decreases activity
multiple interactions
EXP camostat results in decreased activity of PLG protein modified form
camostat inhibits the reaction [PLG protein modified form results in increased expression of CCL2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of CCN2 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
CTD PMID:27773435 NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
JBrowse link
G Rps6 ribosomal protein S6 increases phosphorylation ISO camostat results in increased phosphorylation of RPS6 protein CTD PMID:25104499 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions EXP camostat inhibits the reaction [Adenine results in increased expression of SERPINE1 mRNA] CTD PMID:25766432 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
JBrowse link
G Smad2 SMAD family member 2 multiple interactions ISO camostat inhibits the reaction [Bleomycin results in increased phosphorylation of SMAD2 protein] CTD PMID:26599507 NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation ISO camostat results in increased phosphorylation of STAT3 protein CTD PMID:25104499 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO
EXP
camostat inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]
camostat inhibits the reaction [Adenine results in increased expression of TGFB1 mRNA]; camostat inhibits the reaction [PLG protein modified form results in increased expression of TGFB1 mRNA]
CTD PMID:25766432 PMID:26599507 PMID:27773435 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
camostat inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
camostat inhibits the reaction [PLG protein modified form results in increased expression of TNF mRNA]
CTD PMID:20023007 PMID:27773435 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
carfentanil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases metabolic processing ISO CYP2C8 protein results in increased metabolism of carfentanil CTD PMID:33652071
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing ISO CYP3A4 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases metabolic processing ISO CYP3A5 protein results in increased metabolism of carfentanil CTD PMID:33652071 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
JBrowse link
G Oprm1 opioid receptor, mu 1 multiple interactions ISO Capsaicin inhibits the reaction [carfentanil binds to OPRM1 protein]; Cocaine affects the reaction [carfentanil binds to OPRM1 protein] CTD PMID:12406535 PMID:15953495 NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
JBrowse link
crotamiton term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO crotamiton results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
dimethomorph term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Anxa10 annexin A10 increases expression ISO dimethomorph results in increased expression of ANXA10 mRNA CTD PMID:32194361 NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
JBrowse link
G Ar androgen receptor multiple interactions ISO dimethomorph inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; dimethomorph inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA] CTD PMID:21310686 PMID:33049310 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arg1 arginase 1 decreases expression ISO dimethomorph results in decreased expression of ARG1 mRNA CTD PMID:32194361 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 decreases expression ISO dimethomorph results in decreased expression of CYP2C19 protein CTD PMID:32194361 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 decreases expression ISO dimethomorph results in decreased expression of CYP7A1 mRNA; dimethomorph results in decreased expression of CYP7A1 protein CTD PMID:32194361 NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO dimethomorph binds to and results in increased activity of ESR1 protein CTD PMID:33049310 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO dimethomorph results in decreased expression of G6PC1 mRNA CTD PMID:32194361 NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO dimethomorph binds to and results in increased activity of NR1I2 protein CTD PMID:33049310 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Pde4a phosphodiesterase 4A decreases activity ISO dimethomorph results in decreased activity of PDE4A protein CTD PMID:21251949 NCBI chr 8:19,706,649...19,751,937
Ensembl chr 8:19,703,290...19,751,961
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO dimethomorph binds to and results in increased activity of PPARG protein CTD PMID:33049310 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
dysidenin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc5a5 solute carrier family 5 member 5 multiple interactions ISO dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of perrhenate analog]; dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Iodide analog]; dysidenin inhibits the reaction [SLC5A5 protein results in increased uptake of Sodium Pertechnetate Tc 99m] CTD PMID:12488351 NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
JBrowse link
erastin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acrbp acrosin binding protein increases expression ISO erastin results in increased expression of ACRBP mRNA alternative form CTD PMID:35234341 NCBI chr 4:157,851,149...157,864,211
Ensembl chr 4:157,841,841...157,864,213
JBrowse link
G Atg5 autophagy related 5 increases expression EXP erastin results in increased expression of ATG5 protein CTD PMID:32937103 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Bgn biglycan multiple interactions
decreases expression
ISO BGN mRNA alternative form inhibits the reaction [erastin results in decreased expression of MKI67 protein]; erastin inhibits the reaction [[Antineoplastic Agents, Immunological results in decreased susceptibility to Antineoplastic Agents, Immunological] which results in increased expression of BGN mRNA alternative form]
erastin results in decreased expression of BGN mRNA alternative form
CTD PMID:35234341 NCBI chr  X:151,197,296...151,209,458
Ensembl chr  X:151,197,273...151,209,461
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions
increases expression
ISO GW 506033X inhibits the reaction [erastin results in increased expression of CHAC1 mRNA] CTD PMID:30817950 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression ISO erastin results in increased expression of COL1A2 mRNA alternative form CTD PMID:35234341 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO erastin affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol] CTD PMID:33017621 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
ISO GW 506033X inhibits the reaction [erastin results in increased expression of DDIT3 mRNA] CTD PMID:30817950 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Dtl denticleless E3 ubiquitin protein ligase homolog increases expression ISO erastin results in increased expression of DTL mRNA alternative form CTD PMID:35234341 NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
increases phosphorylation
ISO GW 506033X inhibits the reaction [erastin results in increased phosphorylation of ERN1 protein] CTD PMID:30817950 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
JBrowse link
G Fancd2 FA complementation group D2 decreases expression EXP erastin results in decreased expression of FANCD2 protein CTD PMID:32937103 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
JBrowse link
G Fh fumarate hydratase decreases response to substance ISO FH protein results in decreased susceptibility to erastin CTD PMID:29917289 NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions
increases expression
EXP 3-methyladenine promotes the reaction [erastin results in increased expression of FTH1 protein]; Chloroquine promotes the reaction [erastin results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein] CTD PMID:32937103 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
EXP NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein] CTD PMID:32937103 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions
EXP erastin results in increased expression of GCLM protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]
CTD PMID:32937103 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions ISO GJA1 protein affects the reaction [erastin results in decreased expression of GPX4 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of SLC7A11 protein] CTD PMID:34785303 NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions
ISO
EXP
erastin results in decreased expression of GPX4 protein
gap 27 peptide inhibits the reaction [erastin results in decreased expression of GPX4 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of GPX4 protein]; SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein]
CTD PMID:31323261 PMID:32937103 PMID:34785303 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO erastin results in increased expression of HMOX1 protein CTD PMID:30817950 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hras HRas proto-oncogene, GTPase increases response to substance ISO HRAS protein modified form results in increased susceptibility to erastin CTD PMID:17568748 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 decreases phosphorylation EXP erastin results in decreased phosphorylation of HSPB1 protein CTD PMID:32937103 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions
EXP erastin results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [erastin results in increased expression of MAP1LC3B protein modified form]
CTD PMID:32937103 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
ISO erastin results in increased phosphorylation of MAPK1 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK1 protein]
CTD PMID:30817950 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK3 protein] CTD PMID:30817950 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions
ISO erastin results in increased phosphorylation of MAPK8 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK8 protein]
CTD PMID:30817950 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions
ISO erastin results in decreased expression of MKI67 protein
BGN mRNA alternative form inhibits the reaction [erastin results in decreased expression of MKI67 protein]
CTD PMID:35234341 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Msh2 mutS homolog 2 increases expression ISO erastin results in increased expression of MSH2 mRNA alternative form CTD PMID:35234341 NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
JBrowse link
G Ncoa4 nuclear receptor coactivator 4 decreases expression
multiple interactions
EXP erastin results in decreased expression of NCOA4 protein
3-methyladenine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]; Chloroquine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]
CTD PMID:32937103 NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases expression
ISO
EXP
NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of NFE2L2 protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]
CTD PMID:31323261 PMID:32937103 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
EXP
ISO
erastin results in increased expression of PTGS2 mRNA
Vitamin E inhibits the reaction [erastin analog results in increased expression of PTGS2 mRNA]
erastin analog results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 mRNA
CTD PMID:24439385 PMID:32937103 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Sc5d sterol-C5-desaturase increases expression ISO erastin results in increased expression of SC5D mRNA alternative form CTD PMID:35234341 NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
JBrowse link
G Sesn1 sestrin 1 multiple interactions ISO SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein] CTD PMID:31323261 NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
JBrowse link
G Sesn2 sestrin 2 multiple interactions
increases expression
ISO NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
Acetylcysteine inhibits the reaction [erastin results in increased expression of SESN2 protein]; Butylated Hydroxyanisole inhibits the reaction [erastin results in increased expression of SESN2 protein]; Dactinomycin inhibits the reaction [erastin results in increased expression of SESN2 mRNA]; Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein]; diphenyleneiodonium inhibits the reaction [erastin results in increased expression of SESN2 protein]; ferrostatin-1 inhibits the reaction [erastin results in increased expression of SESN2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of SESN2 mRNA; erastin results in increased expression of SESN2 protein
CTD PMID:31323261 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
JBrowse link
G Slc11a2 solute carrier family 11 member 2 increases expression EXP erastin results in increased expression of SLC11A2 protein CTD PMID:32937103 NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
JBrowse link
G Slc40a1 solute carrier family 40 member 1 decreases expression
increases expression
EXP
ISO
erastin results in decreased expression of SLC40A1 protein
erastin results in increased expression of SLC40A1 protein
CTD PMID:31323261 PMID:32937103 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression
decreases expression
multiple interactions
EXP
ISO
erastin results in increased expression of SLC7A11 mRNA
erastin results in decreased expression of SLC7A11 protein
gap 27 peptide inhibits the reaction [erastin results in decreased expression of SLC7A11 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of SLC7A11 protein]
NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]
CTD PMID:32937103 PMID:34785303 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
JBrowse link
G Taf1a TATA-box binding protein associated factor, RNA polymerase I subunit A decreases expression ISO erastin results in decreased expression of TAF1A mRNA alternative form CTD PMID:35234341 NCBI chr13:95,012,160...95,048,131
Ensembl chr13:95,029,225...95,048,087
JBrowse link
G Tf transferrin increases expression EXP erastin results in increased expression of TF protein CTD PMID:32937103 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
JBrowse link
G Tfrc transferrin receptor increases expression EXP
ISO
erastin results in increased expression of TFRC protein CTD PMID:31323261 PMID:32937103 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 decreases expression ISO erastin results in decreased expression of TIMP1 mRNA alternative form CTD PMID:35234341 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Vdac2 voltage-dependent anion channel 2 decreases expression
affects binding
increases degradation
ISO
EXP
erastin results in decreased expression of VDAC2 protein
erastin analog binds to VDAC2 protein
erastin results in increased degradation of VDAC2 protein
CTD PMID:17568748 PMID:32937103 NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553
JBrowse link
G Vdac3 voltage-dependent anion channel 3 increases degradation
decreases expression
affects response to substance
EXP
ISO
erastin results in increased degradation of VDAC3 protein
erastin results in decreased expression of VDAC3 protein
VDAC3 protein affects the susceptibility to erastin
CTD PMID:17568748 PMID:32937103 NCBI chr16:69,434,982...69,451,473
Ensembl chr16:69,435,005...69,451,471
JBrowse link
G Wdr41 WD repeat domain 41 decreases expression ISO erastin results in decreased expression of WDR41 mRNA alternative form CTD PMID:35234341 NCBI chr 2:26,222,797...26,273,840
Ensembl chr 2:26,224,495...26,273,836
JBrowse link
GSK2656157 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Atf4 activating transcription factor 4 multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein] CTD PMID:30602124 PMID:32578922 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
CTD PMID:30602124 PMID:32357311 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Ostn osteocrin multiple interactions ISO GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA] CTD PMID:30602124 NCBI chr11:73,442,167...73,478,577
Ensembl chr11:73,442,487...73,468,603
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] CTD PMID:32357311 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
ibrutinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alb albumin affects binding ISO ibrutinib binds to ALB protein CTD PMID:26675335 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO ibrutinib results in decreased expression of BCL2L1 mRNA CTD PMID:26254443 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions ISO ibrutinib promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein] CTD PMID:26254443 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO ibrutinib results in decreased expression of BIRC3 mRNA CTD PMID:26254443 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger decreases expression ISO ibrutinib results in decreased expression of BMI1 mRNA CTD PMID:26254443 NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
JBrowse link
G Btk Bruton tyrosine kinase decreases response to substance
decreases activity
decreases phosphorylation
multiple interactions
affects binding
ISO BTK gene mutant form results in decreased susceptibility to ibrutinib; BTK protein mutant form results in decreased susceptibility to ibrutinib
ibrutinib results in decreased activity of BTK protein
ibrutinib results in decreased phosphorylation of BTK protein
(+)-JQ1 compound promotes the reaction [ibrutinib results in decreased phosphorylation of and results in decreased expression of BTK protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of and results in decreased expression of BTK protein]; ibrutinib results in decreased phosphorylation of and results in decreased expression of BTK protein
ibrutinib binds to BTK protein
CTD PMID:23296407 PMID:23425038 PMID:25189416 PMID:26174628 PMID:26254443 More... NCBI chr  X:97,722,796...97,762,315
Ensembl chr  X:97,722,802...97,761,853
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression ISO ibrutinib results in decreased expression of CFLAR mRNA CTD PMID:26254443 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Crebbp CREB binding protein decreases response to substance ISO CREBBP protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
affects metabolic processing
increases metabolic processing
ISO [CYP3A4 protein results in increased metabolism of ibrutinib] which results in increased abundance of PCI-45227
CYP3A4 protein alternative form affects the metabolism of ibrutinib
CTD PMID:34153224 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO ibrutinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Hbb hemoglobin subunit beta affects binding ISO ibrutinib binds to HBB protein CTD PMID:26675335 NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
decreases activity
ISO (+)-JQ1 compound promotes the reaction [ibrutinib results in decreased activity of IKBKB protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased activity of IKBKB protein] CTD PMID:25049379 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO ibrutinib promotes the reaction [CPI203 results in decreased expression of IL10 mRNA]
ibrutinib results in decreased expression of IL10 mRNA
CTD PMID:25049379 PMID:26254443 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il6 interleukin 6 multiple interactions ISO ibrutinib promotes the reaction [CPI203 results in decreased expression of IL6 mRNA] CTD PMID:25049379 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Map3k14 mitogen-activated protein kinase kinase kinase 14 decreases response to substance ISO MAP3K14 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523
JBrowse link
G Nfkbia NFKB inhibitor alpha decreases expression ISO ibrutinib results in decreased expression of NFKBIA mRNA CTD PMID:26254443 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase decreases response to substance ISO PIM1 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
JBrowse link
G Plcg2 phospholipase C, gamma 2 multiple interactions
decreases response to substance
decreases phosphorylation
ISO (+)-JQ1 compound promotes the reaction [ibrutinib results in decreased phosphorylation of PLCG2 protein]; ibrutinib promotes the reaction [(+)-JQ1 compound results in decreased phosphorylation of PLCG2 protein]
PLCG2 protein mutant form results in decreased susceptibility to ibrutinib
CTD PMID:26254443 PMID:27542411 NCBI chr19:45,547,416...45,683,930
Ensembl chr19:45,547,416...45,683,930
JBrowse link
G Prdm1 PR/SET domain 1 decreases expression ISO ibrutinib results in decreased expression of PRDM1 mRNA CTD PMID:26254443 NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit affects localization ISO ibrutinib affects the localization of RELA protein CTD PMID:26254443 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Tnf tumor necrosis factor decreases expression ISO ibrutinib results in decreased expression of TNF mRNA CTD PMID:26254443 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 decreases expression ISO ibrutinib results in decreased expression of TNFAIP3 mRNA CTD PMID:26254443 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
JBrowse link
G Traf2 Tnf receptor-associated factor 2 decreases response to substance ISO TRAF2 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
JBrowse link
G Traf3 Tnf receptor-associated factor 3 decreases response to substance ISO TRAF3 protein mutant form results in decreased susceptibility to ibrutinib CTD PMID:26254443 NCBI chr 6:130,199,696...130,307,168
Ensembl chr 6:130,206,484...130,305,481
JBrowse link
ICI-164384 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egf epidermal growth factor multiple interactions ISO ICI 164384 inhibits the reaction [EGF protein promotes the reaction [Estradiol results in increased expression of OLFM4 mRNA]] CTD PMID:21048224 NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO ICI 164384 inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA] CTD PMID:18629630 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Esr1 estrogen receptor 1 affects binding
multiple interactions
ISO ICI 164384 binds to ESR1 protein
[ICI 164384 binds to and results in increased activity of ESR1 protein] which results in increased expression of HSPB1 mRNA; ICI 164384 binds to and results in increased activity of ESR1 protein
CTD PMID:11162928 PMID:11174852 PMID:19913605 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 affects binding EXP ICI 164384 binds to ESR2 protein CTD PMID:19913605 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 multiple interactions ISO [ICI 164384 binds to and results in increased activity of ESR1 protein] which results in increased expression of HSPB1 mRNA CTD PMID:11174852 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO ICI 164384 inhibits the reaction [Methylmercury Compounds results in increased activity of MAPK1 protein] CTD PMID:15712295 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO ICI 164384 inhibits the reaction [Methylmercury Compounds results in increased activity of MAPK3 protein] CTD PMID:15712295 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Olfm4 olfactomedin 4 multiple interactions ISO ICI 164384 inhibits the reaction [EGF protein promotes the reaction [Estradiol results in increased expression of OLFM4 mRNA]] CTD PMID:21048224 NCBI chr15:55,385,100...55,429,687
Ensembl chr15:55,407,148...55,429,681
JBrowse link
G Pgr progesterone receptor multiple interactions ISO ICI 164384 inhibits the reaction [beta-hexachlorocyclohexane results in increased expression of PGR mRNA]; ICI 164384 inhibits the reaction [Cadmium results in increased expression of PGR protein]; ICI 164384 inhibits the reaction [Endosulfan results in increased expression of PGR mRNA]; ICI 164384 inhibits the reaction [Estradiol results in increased expression of PGR mRNA]; ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of PGR mRNA] CTD PMID:8207012 PMID:16242299 NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
JBrowse link
G Prl prolactin multiple interactions ISO ICI 164384 inhibits the reaction [beta-hexachlorocyclohexane results in increased expression of PRL mRNA]; ICI 164384 inhibits the reaction [Estradiol results in increased expression of PRL mRNA]; ICI 164384 inhibits the reaction [o,p'-DDT results in increased expression of PRL mRNA] CTD PMID:8968093 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
JBrowse link
G Siah2 siah E3 ubiquitin protein ligase 2 multiple interactions
affects response to substance
decreases expression
ISO ICI 164384 inhibits the reaction [[Estradiol co-treated with EGFR protein] results in increased expression of SIAH2 mRNA]
SIAH2 protein affects the susceptibility to ICI 164384
ICI 164384 results in decreased expression of SIAH2 mRNA
CTD PMID:18629630 NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
JBrowse link
G Tff1 trefoil factor 1 multiple interactions ISO ICI 164384 inhibits the reaction [beta-hexachlorocyclohexane results in increased expression of TFF1 mRNA]; ICI 164384 inhibits the reaction [Endosulfan results in increased expression of TFF1 mRNA]; ICI 164384 inhibits the reaction [Estradiol results in increased expression of TFF1 mRNA]; ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of TFF1 mRNA]; ICI 164384 inhibits the reaction [o,p'-DDT results in increased expression of TFF1 mRNA]; ICI 164384 inhibits the reaction [phenothrin results in increased expression of TFF1 mRNA] CTD PMID:8968093 PMID:10064545 PMID:16242299 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
loratadine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity
multiple interactions
ISO Loratadine results in decreased activity of ABCB11 protein
Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
CTD PMID:23956101 PMID:24014644 PMID:28437613 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A affects response to substance
increases export
ISO ABCB1A protein affects the susceptibility to Loratadine
ABCB1 protein results in increased export of Loratadine
CTD PMID:12584158 PMID:15502009 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B affects response to substance ISO ABCB1B protein affects the susceptibility to Loratadine CTD PMID:15502009 NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO Loratadine results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases response to substance ISO ABCC1 protein results in decreased susceptibility to Loratadine CTD PMID:22095822 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions ISO Loratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril] CTD PMID:22095822 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Ace2 angiotensin I converting enzyme 2 affects binding ISO Loratadine binds to ACE2 protein CTD PMID:33609497 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Alox5 arachidonate 5-lipoxygenase decreases activity ISO Loratadine analog results in decreased activity of ALOX5 protein CTD PMID:15482930 NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Loratadine results in decreased expression of AP1S1 mRNA CTD PMID:17567588 NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
JBrowse link
G Ar androgen receptor increases expression ISO Loratadine results in increased expression of AR mRNA CTD PMID:16407038 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression ISO Loratadine results in increased expression of ASNS mRNA CTD PMID:15342952 PMID:17567588 NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
JBrowse link
G Casp3 caspase 3 increases cleavage
increases activity
multiple interactions
ISO Loratadine results in increased cleavage of CASP3 protein
Loratadine results in increased activity of CASP3 protein
Dasatinib promotes the reaction [Loratadine results in increased activity of CASP3 protein]; midostaurin promotes the reaction [Loratadine results in increased activity of CASP3 protein]; Palmitic Acid promotes the reaction [Loratadine results in increased activity of CASP3 protein]
CTD PMID:20570632 PMID:22700542 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions
ISO Loratadine results in increased activity of CASP7 protein
Palmitic Acid promotes the reaction [Loratadine results in increased activity of CASP7 protein]
CTD PMID:22700542 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 increases cleavage ISO Loratadine results in increased cleavage of CASP8 protein CTD PMID:20570632 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 increases cleavage ISO Loratadine results in increased cleavage of CASP9 protein CTD PMID:20570632 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO Loratadine results in decreased activity of CYP2C8 protein CTD PMID:15601807
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 gene polymorphism affects the metabolism of Loratadine; CYP2D6 protein affects the metabolism of Loratadine CTD PMID:15932952 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity ISO Loratadine analog results in decreased activity of CYP3A4 protein; Loratadine results in decreased activity of CYP3A4 protein CTD PMID:15482930 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Esr1 estrogen receptor 1 increases expression ISO Loratadine results in increased expression of ESR1 mRNA CTD PMID:16407038 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Fabp1 fatty acid binding protein 1 increases expression ISO Loratadine results in increased expression of FABP1 mRNA CTD PMID:15342952 PMID:17567588 NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
JBrowse link
G Gdpd3 glycerophosphodiester phosphodiesterase domain containing 3 increases expression ISO Loratadine results in increased expression of GDPD3 mRNA CTD PMID:15342952 NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
JBrowse link
G Hpn hepsin increases expression ISO Loratadine results in increased expression of HPN mRNA CTD PMID:15342952 NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
JBrowse link
G Hrh1 histamine receptor H 1 affects binding ISO Loratadine analog binds to HRH1 protein; Loratadine binds to HRH1 protein CTD PMID:15482930 NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
JBrowse link
G Inhbe inhibin subunit beta E increases expression ISO Loratadine results in increased expression of INHBE mRNA CTD PMID:15342952 PMID:17567588 NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity
multiple interactions
affects activity
ISO Loratadine results in decreased activity of KCNH2 protein
[desloratadine co-treated with Loratadine] results in decreased activity of KCNH2 protein; [Ketoconazole co-treated with desloratadine co-treated with Loratadine] results in decreased activity of KCNH2 protein; [Ketoconazole co-treated with Loratadine] results in decreased activity of KCNH2 protein; Loratadine binds to and results in decreased activity of KCNH2 protein; Loratadine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Loratadine affects the activity of KCNH2 protein
CTD PMID:9658196 PMID:10604956 PMID:11705456 PMID:16278312 PMID:21158687 More... NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
JBrowse link
G Lss lanosterol synthase increases expression ISO Loratadine results in increased expression of LSS mRNA CTD PMID:15342952 NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
JBrowse link
G Nr0b2 nuclear receptor subfamily 0, group B, member 2 increases expression ISO Loratadine results in increased expression of NR0B2 mRNA CTD PMID:15342952 NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator increases expression ISO Loratadine results in increased expression of NUPR1 mRNA CTD PMID:15342952 PMID:17567588 NCBI chr 1:181,213,292...181,215,327 JBrowse link
G Rps6 ribosomal protein S6 decreases expression ISO Loratadine results in decreased expression of RPS6 protein modified form CTD PMID:20570632 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N increases expression ISO Loratadine results in increased expression of SERPINA3 mRNA CTD PMID:15342952 NCBI chr 6:123,323,632...123,331,166
Ensembl chr 6:123,323,629...123,332,433
JBrowse link
G Slc2a3 solute carrier family 2 member 3 decreases expression ISO Loratadine results in decreased expression of SLC2A3 mRNA CTD PMID:15342952 PMID:17567588 NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO Loratadine results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
JBrowse link
G Tagln transgelin decreases expression ISO Loratadine results in decreased expression of TAGLN mRNA CTD PMID:15342952 PMID:17567588 NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
JBrowse link
mefenacet term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ar androgen receptor multiple interactions ISO Dihydrotestosterone inhibits the reaction [mefenacet results in increased activity of AR protein] CTD PMID:15064155 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO CYP2B6 protein results in increased metabolism of and results in decreased susceptibility to mefenacet CTD PMID:15853388 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO mefenacet binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
PHA-665752 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of AKT1 protein] CTD PMID:22040890 PMID:25002221 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of BCL2L1 protein CTD PMID:20661229 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein
Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased cleavage of CASP3 protein]
CTD PMID:20661229 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [arsenite results in decreased expression of CAT protein] CTD PMID:22040890 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Egfr epidermal growth factor receptor decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]
CTD PMID:21266357 NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein] CTD PMID:20661229 PMID:21812414 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
increases mutagenesis
decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased activity of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of and results in increased activity of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [HGF protein results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one inhibits the reaction [ochratoxin A results in increased phosphorylation of MET protein]; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of and results in decreased activity of MET protein; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Cisplatin promotes the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]
CTD PMID:20661229 PMID:21106725 PMID:21266357 PMID:21812414 PMID:25002221 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
CTD PMID:21266357 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
increases response to substance
increases expression
ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA; Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA; 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein
CTD PMID:21266357 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased expression of XIAP protein CTD PMID:20661229 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700
JBrowse link
piperine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression
ISO Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]
piperine results in increased expression of ABCB1 mRNA; piperine results in increased expression of ABCB1 protein
CTD PMID:23707768 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] CTD PMID:25087745 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein] CTD PMID:25655587 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Alb albumin multiple interactions EXP piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in decreased expression of ALB protein]] CTD PMID:17429802 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
JBrowse link
G Atf2 activating transcription factor 2 decreases localization ISO piperine results in decreased localization of ATF2 protein CTD PMID:15531295 NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions
ISO piperine results in increased expression of BAX protein
piperine inhibits the reaction [Curcumin results in decreased expression of BAX protein]
CTD PMID:28341137 PMID:30935902 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO piperine results in decreased expression of BCL2 protein
[piperine co-treated with Curcumin] results in decreased expression of BCL2 protein
CTD PMID:28341137 PMID:30935902 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
ISO piperine inhibits the reaction [Cadmium results in increased activity of CASP3 protein]
piperine inhibits the reaction [Curcumin results in decreased expression of CASP3 protein]
piperine results in increased cleavage of CASP3 protein
CTD PMID:16780805 PMID:28341137 PMID:30935902 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 increases cleavage ISO piperine results in increased cleavage of CASP9 protein CTD PMID:28341137 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions
decreases expression
EXP
ISO
piperine inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]
piperine results in decreased expression of CAT protein
CTD PMID:25087745 PMID:28341137 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein] CTD PMID:25655587 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO piperine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] CTD PMID:30935902 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein] CTD PMID:25655587 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein] CTD PMID:25655587 NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein] CTD PMID:25655587 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein] CTD PMID:25655587 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein] CTD PMID:25655587 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of CDKN1A protein CTD PMID:30935902 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases localization ISO piperine results in decreased localization of CREB1 protein CTD PMID:15531295 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Csf2 colony stimulating factor 2 decreases secretion
decreases expression
ISO piperine results in decreased secretion of CSF2 protein
piperine results in decreased expression of CSF2 mRNA
CTD PMID:15531295 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of CTNNB1 protein CTD PMID:30935902 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO piperine affects the localization of CYCS protein CTD PMID:28341137 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO piperine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:17012224 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases expression
ISO [piperine co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]
piperine results in increased expression of CYP3A4 mRNA; piperine results in increased expression of CYP3A4 protein
CTD PMID:23707768 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 affects binding ISO piperine binds to FGFR1 protein CTD PMID:28341137 NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases localization
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of FOS protein]
piperine results in decreased localization of FOS protein
CTD PMID:15531295 PMID:21354279 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]; sodium-4,5-dihydroxy-1,3-benzene disulfonate promotes the reaction [piperine inhibits the reaction [beryllium nitrate results in increased activity of GPT protein]] CTD PMID:17429802 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] CTD PMID:25087745 NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO
EXP
[Curcumin co-treated with piperine] results in increased expression of HMOX1 mRNA; [Curcumin co-treated with piperine] results in increased expression of HMOX1 protein; Acetylcysteine inhibits the reaction [[Curcumin co-treated with piperine] results in increased expression of HMOX1 protein]
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein]
CTD PMID:12806184 PMID:23942037 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]; tin protoporphyrin IX inhibits the reaction [[Curcumin co-treated with piperine] inhibits the reaction [IFNG protein results in increased abundance of Nitrites]] CTD PMID:23942037 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Igf1r insulin-like growth factor 1 receptor affects binding ISO piperine binds to IGF1R protein CTD PMID:28341137 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Il1b interleukin 1 beta decreases expression
decreases secretion
ISO piperine results in decreased expression of IL1B mRNA
piperine results in decreased secretion of IL1B protein
CTD PMID:15531295 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased expression of CCNB1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDC25C protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK1 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK4 protein]; piperine inhibits the reaction [IL2 protein results in increased expression of CDK6 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:25655587 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il6 interleukin 6 decreases secretion
decreases expression
ISO piperine results in decreased secretion of IL6 protein
piperine results in decreased expression of IL6 mRNA
CTD PMID:15531295 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of JUN protein] CTD PMID:21354279 PMID:22542552 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] CTD PMID:25087745 NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
JBrowse link
G Lep leptin multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in increased expression of LEP protein] CTD PMID:25087745 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP piperine inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] CTD PMID:25087745 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
JBrowse link
G Maoa monoamine oxidase A multiple interactions
decreases activity
ISO
EXP
[resveratrol co-treated with piperine] results in decreased activity of MAOA protein
piperine results in decreased activity of MAOA protein
CTD PMID:15120460 PMID:23943324 NCBI chr  X:6,032,172...6,098,308
Ensembl chr  X:6,030,795...6,099,593
JBrowse link
G Maob monoamine oxidase B decreases activity EXP piperine results in decreased activity of MAOB protein CTD PMID:15120460 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
CTD PMID:21354279 PMID:22542552 PMID:25655587 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
piperine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
CTD PMID:21354279 PMID:22542552 PMID:25655587 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase affects binding ISO piperine binds to MET protein CTD PMID:28341137 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP14 protein] CTD PMID:21354279 NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression ISO piperine results in decreased expression of MMP2 protein CTD PMID:15531295 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]
piperine results in decreased expression of MMP9 protein
CTD PMID:15531295 PMID:21354279 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Ncoa1 nuclear receptor coactivator 1 multiple interactions ISO Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein] CTD PMID:23707768 NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases localization ISO piperine results in decreased localization of NFKB1 protein CTD PMID:15531295 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
CTD PMID:21354279 PMID:22542552 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions
increases expression
increases activity
affects binding
ISO [piperine co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [piperine results in increased expression of CYP3A4 protein]; piperine promotes the reaction [NCOA1 protein binds to NR1I2 protein]
piperine results in increased expression of NR1I2 protein
piperine results in increased activity of NR1I2 protein
piperine binds to NR1I2 protein
CTD PMID:23707768 PMID:25455453 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of PRKCA protein] CTD PMID:21354279 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] CTD PMID:22542552 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rel REL proto-oncogene, NF-kB subunit decreases localization ISO piperine results in decreased localization of REL protein CTD PMID:15531295 NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases localization
ISO piperine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of RELA protein]
piperine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and affects the localization of RELA protein]
piperine results in decreased localization of RELA protein
CTD PMID:15531295 PMID:21354279 PMID:22542552 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Slc9a3 solute carrier family 9 member A3 multiple interactions EXP [piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein] CTD PMID:12806184 NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT3 protein] CTD PMID:25655587 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
JBrowse link
G Stat5a signal transducer and activator of transcription 5A multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein] CTD PMID:25655587 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO piperine inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein] CTD PMID:25655587 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
JBrowse link
G Tac1 tachykinin, precursor 1 decreases expression EXP piperine results in decreased expression of TAC1 protein CTD PMID:6205719 NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
JBrowse link
G Tgfbr1 transforming growth factor, beta receptor 1 affects binding ISO piperine binds to TGFBR1 protein CTD PMID:28341137 NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
JBrowse link
G Tnf tumor necrosis factor decreases expression
decreases secretion
ISO piperine results in decreased expression of TNF mRNA
piperine results in decreased secretion of TNF protein
CTD PMID:15531295 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [piperine co-treated with Curcumin] results in decreased expression of TP53 protein CTD PMID:30935902 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Ugdh UDP-glucose 6-dehydrogenase decreases expression ISO piperine results in decreased expression of UGDH mRNA CTD PMID:16292757 NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
JBrowse link
G Utrn utrophin increases expression ISO piperine results in increased expression of UTRN mRNA CTD PMID:22028826 NCBI chr 1:6,720,854...7,224,313
Ensembl chr 1:6,722,594...7,224,313
JBrowse link
quinaprilat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO quinaprilat inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions ISO
EXP
quinaprilat inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
JBrowse link
SCH772984 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] CTD PMID:31706003 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adm adrenomedullin decreases secretion
multiple interactions
EXP SCH772984 results in decreased secretion of ADM protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein]
CTD PMID:28087833 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G App amyloid beta precursor protein multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] CTD PMID:28087833 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of and results in increased expression of CREB1 protein]; SCH772984 results in decreased phosphorylation of and results in decreased expression of CREB1 protein CTD PMID:28087833 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] CTD PMID:28087833 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 mRNA]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of CYP2E1 protein] CTD PMID:31585129 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases secretion
EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein]
SCH772984 results in increased secretion of FGF2 protein
CTD PMID:28087833 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [SCH772984 co-treated with bilobalide] inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]]; SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; SCH772984 inhibits the reaction [Oxaliplatin promotes the reaction [Morphine results in increased expression of FOS protein]] CTD PMID:28087833 PMID:32319158 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G Gpr4 G protein-coupled receptor 4 multiple interactions ISO SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein] CTD PMID:33161135 NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599
JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions EXP SCH772984 inhibits the reaction [APP protein modified form results in increased expression of GRK2 protein] CTD PMID:30399361 NCBI chr 1:201,581,480...201,601,580
Ensembl chr 1:201,581,480...201,601,582
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] CTD PMID:28087833
G Il6 interleukin 6 multiple interactions EXP SCH772984 promotes the reaction [diphenylarsinic acid results in increased secretion of IL6 protein] CTD PMID:28087833 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein] CTD PMID:28087833 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K1 protein CTD PMID:28087833 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 increases phosphorylation EXP SCH772984 results in increased phosphorylation of MAP2K2 protein CTD PMID:28087833 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
decreases expression
decreases activity
EXP
ISO
SCH772984 results in increased phosphorylation of MAPK1 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK1 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK1 protein]
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]
SCH772984 results in decreased expression of MAPK1 protein
SCH772984 results in decreased activity of MAPK1 protein
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases activity
decreases expression
multiple interactions
increases phosphorylation
EXP
ISO
SCH772984 results in decreased activity of MAPK3 protein
SCH772984 results in decreased expression of MAPK3 protein
SCH772984 inhibits the reaction [GPR4 protein affects the phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [Ozone results in increased phosphorylation of MAPK3 protein]; SCH772984 inhibits the reaction [saikosaponin D results in increased phosphorylation of and results in increased activity of MAPK3 protein]
SCH772984 results in increased phosphorylation of MAPK3 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]
CTD PMID:28087833 PMID:29925859 PMID:32822868 PMID:33161135 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 decreases expression
multiple interactions
EXP SCH772984 results in decreased expression of MAPK8 protein
SCH772984 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK8 protein]
CTD PMID:28087833 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP SCH772984 inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein] CTD PMID:28087833 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of and results in increased phosphorylation of SP1 protein]; SCH772984 inhibits the reaction [Ethylene Chlorohydrin results in increased expression of SP1 mRNA] CTD PMID:31585129 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
JBrowse link
G Spi1 Spi-1 proto-oncogene multiple interactions ISO SCH772984 inhibits the reaction [saikosaponin D results in increased expression of SPI1 protein] CTD PMID:32822868 NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Vim vimentin multiple interactions ISO SCH772984 inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] CTD PMID:31706003 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
spirapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ren renin increases expression
multiple interactions
EXP spirapril results in increased expression of REN mRNA; spirapril results in increased expression of REN protein
spirapril promotes the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein]
CTD PMID:1764812 PMID:9300315 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO spirapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions ISO
EXP
spirapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
JBrowse link
trandolapril term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity EXP trandolapril results in decreased activity of ACE protein CTD PMID:27428043 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ace2 angiotensin I converting enzyme 2 multiple interactions ISO trandolapril promotes the reaction [REN2 protein results in increased expression of ACE2 protein] CTD PMID:27428043 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Ache acetylcholinesterase multiple interactions EXP trandolapril inhibits the reaction [3-nitropropionic acid results in increased activity of ACHE protein] CTD PMID:25445565 NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Adrb1 adrenoceptor beta 1 increases expression EXP trandolapril results in increased expression of ADRB1 protein CTD PMID:7586371 NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
JBrowse link
G Agt angiotensinogen multiple interactions
decreases expression
EXP
ISO
trandolapril inhibits the reaction [Isoproterenol results in increased expression of AGT protein]
trandolapril inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]
trandolapril results in decreased expression of AGT protein modified form
CTD PMID:1534315 PMID:27428043 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Cat catalase multiple interactions EXP trandolapril inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein] CTD PMID:25445565 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
decreases expression
EXP [trandolapril co-treated with eplerenone] results in decreased expression of CYBA mRNA
trandolapril results in decreased expression of CYBA mRNA
CTD PMID:17324946 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Fn1 fibronectin 1 multiple interactions EXP [trandolapril co-treated with eplerenone] results in decreased expression of FN1 protein CTD PMID:17324946 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions
decreases expression
EXP [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 mRNA; [trandolapril co-treated with eplerenone] results in decreased expression of NCF1 protein
trandolapril results in decreased expression of NCF1 mRNA; trandolapril results in decreased expression of NCF1 protein
CTD PMID:17324946 NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
JBrowse link
G Ren renin multiple interactions
increases expression
ISO
EXP
[Bumetanide co-treated with trandolapril] results in increased expression of REN protein
trandolapril results in increased expression of REN protein
CTD PMID:16635047 PMID:27428043 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO trandolapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
JBrowse link
G Slc15a2 solute carrier family 15 member 2 multiple interactions EXP trandolapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] CTD PMID:18713951 NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP trandolapril results in increased expression of SOD2 protein CTD PMID:17324946 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
JBrowse link
ximelagatran term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G F2 coagulation factor II decreases cleavage
multiple interactions
ISO ximelagatran results in decreased cleavage of F2 protein
ximelagatran binds to and results in decreased activity of F2 protein
CTD PMID:15155122 PMID:16084352 PMID:16194202 PMID:17314111 NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20072
    chemical entity 20071
      atom 20071
        nonmetal atom 19963
          nitrogen atom 19043
            nitrogen molecular entity 19043
              organonitrogen compound 18842
                carboxamide 17602
                  tertiary carboxamide 223
                    (2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid 0
                    (2R,3R,3aS,9bS)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-1-[cyclohexyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                    (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                    (2S,3S,3aR,9bR)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                    (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                    (4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone 0
                    (E)-dimethomorph + 10
                    (E)-flumorph + 0
                    (Z)-dimethomorph + 10
                    (Z)-flumorph + 0
                    1-(4-\{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl\}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone + 0
                    1-(phenanthren-2-ylcarbonyl)piperazine-2,3-dicarboxylic acid + 0
                    1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one 0
                    1-methyl-1-[1-oxo-1-(10H-phenothiazin-10-yl)propan-2-yl]pyrrolidinium + 0
                    1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester 0
                    2,2-dichloro-1-[5-(furan-2-yl)-2,2-dimethyl-1,3-oxazolidin-3-yl]ethanone + 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                    2-[(ethanesulfonyl)amino]-5-fluoro-4-[4-methyl-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]benzene-1-carbothioamide + 0
                    2-\{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy\}-N-(2-fluorophenyl)-N-methylpropanamide + 0
                    2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester 0
                    2-chloro-N-(2,6-dimethylphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide + 0
                    3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                    4-(dichloroacetyl)piperazine-1-carbaldehyde 0
                    4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 0
                    AZD1979 oxetane hydrolysis product 0
                    AZD7545 0
                    Adenocarpine 0
                    Allidochlor 0
                    Astrophylline 0
                    Casimiroedine 0
                    Dichlormid 0
                    Ethyl 3-(N-butylacetamido)propionate 0
                    GSK1016790A 0
                    GSK2656157 4
                    HMMF 0
                    ICI-164384 12
                    LSM-14399 0
                    LSM-17487 0
                    LSM-17508 0
                    LSM-17532 0
                    LSM-17538 0
                    LSM-17628 0
                    LSM-17680 0
                    LSM-17740 0
                    LSM-25340 0
                    LSM-25384 0
                    LSM-25403 0
                    LSM-25515 0
                    LSM-25525 0
                    LSM-25537 0
                    LSM-25565 0
                    LSM-25598 0
                    LSM-9991 0
                    MK 351A 0
                    MK-8353 0
                    ML-210 0
                    ML162 0
                    N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                    N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                    N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                    N-(p-octylbenzoyl)-piperidin-4-ol 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                    N-[(Z)-11-methyldodec-2-enoyl]piperidine 0
                    N-[(Z)-dodec-2-enoyl]morpholine 0
                    N-[(Z)-dodec-2-enoyl]piperidine 0
                    N-[(Z)-dodec-2-enoyl]pyrrolidine 0
                    N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                    N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                    N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                    N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                    N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                    N-isovalerylsarcosine 0
                    N1,N5,N10-Tricaffeoyl spermidine 0
                    OSMI-1 0
                    PF-06446846 0
                    PHA-533533 0
                    PHA-665752 12
                    R-29148 0
                    RSL3 0
                    SCH772984 24
                    SIS3 free base 0
                    acalabrutinib 3
                    althiomycin 0
                    butachlor 7
                    camostat 28
                    carfentanil 4
                    celacinnine 0
                    crotamiton 1
                    cyproflanilide 0
                    dalfopristin 0
                    delgocitinib 0
                    diloxanide furoate 0
                    dysidenin 1
                    erastin 41
                    ibrutinib 24
                    ivosidenib 0
                    lofentanyl 0
                    loratadine 33
                    mefenacet 3
                    methylprednisolone 21-suleptanic acid ester 0
                    narlaprevir 0
                    nigerazine A 0
                    nigerazine B 0
                    nigragillin 0
                    nirmatrelvir + 0
                    onalespib 0
                    orthosulfamuron 0
                    piperine 64
                    pipobroman 0
                    pristinamycin IIA + 0
                    promysalin 0
                    pyrimorph 0
                    quinapril 0
                    quinaprilat 2
                    somocystinamide A 0
                    sotorasib 0
                    spirapril 3
                    spiraprilat + 3
                    trandolapril 13
                    trandolaprilat + 13
                    tyclopyrazoflor 0
                    ximelagatran 1
                    ximelagatran (hydroxylamine form) 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20072
    subatomic particle 20071
      composite particle 20071
        hadron 20071
          baryon 20071
            nucleon 20071
              atomic nucleus 20071
                atom 20071
                  main group element atom 19974
                    p-block element atom 19974
                      carbon group element atom 19903
                        carbon atom 19896
                          organic molecular entity 19896
                            organic group 18994
                              organic divalent group 18980
                                organodiyl group 18980
                                  carbonyl group 18933
                                    carbonyl compound 18933
                                      carboxylic acid 18629
                                        carboacyl group 17761
                                          univalent carboacyl group 17761
                                            carbamoyl group 17602
                                              carboxamide 17602
                                                tertiary carboxamide 223
                                                  (2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid 0
                                                  (2R,3R,3aS,9bS)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-1-[cyclohexyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (2R,3R,3aS,9bS)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2R,3R,3aS,9bS)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester 0
                                                  (2S,3R)-N'-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide 0
                                                  (2S,3S,3aR,9bR)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-7-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-7-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-(2-methoxyphenyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-1-[1-oxo-2-(3-pyridinyl)ethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid methyl ester 0
                                                  (2S,3S,3aR,9bR)-7-(3-fluorophenyl)-3-(hydroxymethyl)-6-oxo-1-(pyridine-2-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxylic acid 0
                                                  (4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone 0
                                                  (E)-dimethomorph + 10
                                                  (E)-flumorph + 0
                                                  (Z)-dimethomorph + 10
                                                  (Z)-flumorph + 0
                                                  1-(4-\{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl\}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone + 0
                                                  1-(phenanthren-2-ylcarbonyl)piperazine-2,3-dicarboxylic acid + 0
                                                  1-[4-(1-oxoprop-2-enyl)-1-piperazinyl]-2-propen-1-one 0
                                                  1-methyl-1-[1-oxo-1-(10H-phenothiazin-10-yl)propan-2-yl]pyrrolidinium + 0
                                                  1-methyl-4-[2-oxo-2-(N-(phenylmethyl)anilino)ethyl]-5-pyrrolo[3,2-b]pyrrolecarboxylic acid propan-2-yl ester 0
                                                  2,2-dichloro-1-[5-(furan-2-yl)-2,2-dimethyl-1,3-oxazolidin-3-yl]ethanone + 0
                                                  2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(pyrazine-2-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(2-pyrazinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-fluorophenyl)methyl]acetamide 0
                                                  2-[(ethanesulfonyl)amino]-5-fluoro-4-[4-methyl-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl]benzene-1-carbothioamide + 0
                                                  2-\{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy\}-N-(2-fluorophenyl)-N-methylpropanamide + 0
                                                  2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester 0
                                                  2-chloro-N-(2,6-dimethylphenyl)-N-(2-oxotetrahydrofuran-3-yl)acetamide + 0
                                                  3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide 0
                                                  4-(dichloroacetyl)piperazine-1-carbaldehyde 0
                                                  4-[dimethylamino(oxo)methyl]-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 0
                                                  AZD1979 oxetane hydrolysis product 0
                                                  AZD7545 0
                                                  Adenocarpine 0
                                                  Allidochlor 0
                                                  Astrophylline 0
                                                  Casimiroedine 0
                                                  Dichlormid 0
                                                  Ethyl 3-(N-butylacetamido)propionate 0
                                                  GSK1016790A 0
                                                  GSK2656157 4
                                                  HMMF 0
                                                  ICI-164384 12
                                                  LSM-14399 0
                                                  LSM-17487 0
                                                  LSM-17508 0
                                                  LSM-17532 0
                                                  LSM-17538 0
                                                  LSM-17628 0
                                                  LSM-17680 0
                                                  LSM-17740 0
                                                  LSM-25340 0
                                                  LSM-25384 0
                                                  LSM-25403 0
                                                  LSM-25515 0
                                                  LSM-25525 0
                                                  LSM-25537 0
                                                  LSM-25565 0
                                                  LSM-25598 0
                                                  LSM-9991 0
                                                  MK 351A 0
                                                  MK-8353 0
                                                  ML-210 0
                                                  ML162 0
                                                  N,N,4-trimethyl-2-[(1-oxo-3-phenylprop-2-enyl)amino]-5-thiazolecarboxamide 0
                                                  N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide 0
                                                  N-(4-\{[(1H-benzotriazol-1-yl)acetyl][(thiophen-3-yl)methyl]amino\}phenyl)propanamide 0
                                                  N-(p-octylbenzoyl)-piperidin-4-ol 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aS,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide 0
                                                  N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(2S,4aS,12aS)-2-[2-[[(3S)-1-benzylpyrrolidin-3-yl]amino]-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide 0
                                                  N-[(Z)-11-methyldodec-2-enoyl]piperidine 0
                                                  N-[(Z)-dodec-2-enoyl]morpholine 0
                                                  N-[(Z)-dodec-2-enoyl]piperidine 0
                                                  N-[(Z)-dodec-2-enoyl]pyrrolidine 0
                                                  N-[1-[(2,6-dimethylanilino)-oxomethyl]cyclopentyl]-N-(phenylmethyl)-4-(1-tetrazolyl)benzamide 0
                                                  N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide 0
                                                  N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide 0
                                                  N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2R,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(2S,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide 0
                                                  N-\{4-[(1H-benzotriazol-1-ylacetyl)(thiophen-3-ylmethyl)amino]phenyl\}-2-methylpropanamide 0
                                                  N-isovalerylsarcosine 0
                                                  N1,N5,N10-Tricaffeoyl spermidine 0
                                                  OSMI-1 0
                                                  PF-06446846 0
                                                  PHA-533533 0
                                                  PHA-665752 12
                                                  R-29148 0
                                                  RSL3 0
                                                  SCH772984 24
                                                  SIS3 free base 0
                                                  acalabrutinib 3
                                                  althiomycin 0
                                                  butachlor 7
                                                  camostat 28
                                                  carfentanil 4
                                                  celacinnine 0
                                                  crotamiton 1
                                                  cyproflanilide 0
                                                  dalfopristin 0
                                                  delgocitinib 0
                                                  diloxanide furoate 0
                                                  dysidenin 1
                                                  erastin 41
                                                  ibrutinib 24
                                                  ivosidenib 0
                                                  lofentanyl 0
                                                  loratadine 33
                                                  mefenacet 3
                                                  methylprednisolone 21-suleptanic acid ester 0
                                                  narlaprevir 0
                                                  nigerazine A 0
                                                  nigerazine B 0
                                                  nigragillin 0
                                                  nirmatrelvir + 0
                                                  onalespib 0
                                                  orthosulfamuron 0
                                                  piperine 64
                                                  pipobroman 0
                                                  pristinamycin IIA + 0
                                                  promysalin 0
                                                  pyrimorph 0
                                                  quinapril 0
                                                  quinaprilat 2
                                                  somocystinamide A 0
                                                  sotorasib 0
                                                  spirapril 3
                                                  spiraprilat + 3
                                                  trandolapril 13
                                                  trandolaprilat + 13
                                                  tyclopyrazoflor 0
                                                  ximelagatran 1
                                                  ximelagatran (hydroxylamine form) 0
paths to the root